Bill > HB3717

This bill establishes a comprehensive grant program in Texas to fund drug development trials for ibogaine, a psychoactive substance with potential therapeutic applications, aimed at securing FDA approval for treating opioid use disorder, co-occurring substance use disorders, and other neurological or mental health conditions. The Texas Health and Human Services Commission will create a grant program that solicits applications from for-profit, nonprofit, or public benefit entities capable of conducting FDA drug development trials, with specific requirements including a detailed trial design, patient screening protocols, cardiac safety measures, and plans for intellectual property recognition, treatment accessibility, and medical provider training. A selection committee composed of subject matter experts, philanthropic partners, and legislative designees will review applications and recommend the most qualified applicant. The selected applicant must submit an investigational new drug application, seek breakthrough therapy designation, establish drug development trial sites with cardiac intensive care capabilities, and begin treatment trials under the oversight of a state-based institutional review board. The program will be funded through state appropriations, gifts, grants, and donations, with the selected applicant required to match the state's financial contribution. The bill aims to position Texas as a leader in ibogaine research and potential treatment development, with provisions for federal authorization and an effective date contingent on legislative approval.

Health and Social Services

https://capitol.texas.gov/BillLookup/History.aspx?LegSess=89R&Bill=HB3717